Skip to content
How It Works
Explore
Ask a Question Resources Pricing
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Sign Up
PubMed This is a summary of 25 peer-reviewed journal articles Updated
Hematology · Hemoglobin E-beta-thalassemia

The Biology and Diagnosis of HbE/Beta-Thalassemia

At a Glance

HbE/beta-thalassemia results from inheriting an HbE variant and a beta-thalassemia allele, which reduce beta-globin production. HPLC or electrophoresis may overlap with other conditions, so molecular DNA testing can confirm the genotype and clarify severity modifiers.

Understanding the biology behind HbE/beta-thalassemia helps explain why this condition is so unique and why getting a clear diagnosis can sometimes be a multi-step process.

The Biological Imbalance

At its core, this condition is a problem of balance. To make healthy hemoglobin (the oxygen-carrier in your blood), your body needs equal amounts of “alpha” and “beta” globin chains.

In HbE/beta-thalassemia, your body inherits two different instructions that disrupt this balance:

  1. The HbE Variant (c.79G>A): This is a variant that creates a “cryptic splice site”—an alteration in the genetic code that causes the body to accidentally discard some of the instructions for making beta-globin [1][2].
  2. The Beta-Thalassemia Allele: This second instruction either reduces (beta-plus) or completely stops (beta-zero) the production of beta-globin [2].

Because you have two sets of instructions telling the body to make less beta-globin, you end up with a large excess of “alpha” chains. These leftover alpha chains are unstable; they clump together and damage the red blood cells before they can even leave the bone marrow. This process is called ineffective erythropoiesis [3][4]. The red blood cells that do make it into the bloodstream are often fragile and are destroyed quickly, leading to hemolysis (red blood cell breakdown) [2][5].

Why Diagnosis Can Be Tricky

The most common initial test is HPLC (High-Performance Liquid Chromatography) or hemoglobin electrophoresis. These tests sort different types of hemoglobin. However, they aren’t always definitive for HbE/beta-thalassemia because:

  • The “Trait” Overlap: If a person has a very low level of HbF (fetal hemoglobin) or specific beta mutations, their HPLC results can look nearly identical to someone who is just a “carrier” (HbE trait). Additionally, on some platforms, HbE and HbA2 co-elute (combine) and are difficult to separate [6][7].
  • Look-Alikes: Other conditions, like HbE homozygosity (inheriting HbE from both parents), HbE/beta-plus-thalassemia, or iron deficiency, can create similar patterns on a standard blood count [8][9].
  • Transfusion Interference: If a patient recently had a blood transfusion, the donor’s blood will show up on the test, potentially masking the patient’s true hemoglobin pattern [6][10].

Molecular Testing

Because of these overlaps, doctors integrate clinical findings, blood counts, and hemoglobin analysis with molecular testing (DNA testing) to confirm the diagnosis and define the genotype.

  • Targeted PCR Panels: These look for the most common mutations found in specific geographic regions [11][12].
  • Sanger Sequencing: This is used to “read” the beta-globin gene to find variants that a standard panel might miss [11][13].
  • Deletion Testing: Large missing pieces of DNA (deletions) require specialized testing like MLPA or Gap-PCR. A negative limited panel does not entirely exclude the disease [14][15].

Genetic Modifiers: Why Severity Varies

Even two people with the exact same beta-thalassemia mutation can have very different symptoms. This is because of “modifiers”:

  • Fetal Hemoglobin (HbF) Modifiers: Variants in regions like BCL11A, XmnI, or HBS1L-MYB can help maintain fetal hemoglobin production into adulthood. This “extra” hemoglobin can partially take the place of the missing beta-globin, often leading to milder anemia [16][17][18]. Testing for these is specialized and does not perfectly predict an individual course.
  • Alpha-Globin Deletions: If you also happen to inherit a “missing” alpha-globin gene (alpha-thalassemia), it can actually help. By having fewer alpha chains, the balance is partially restored, which can reduce severity [18][19].
  • Alpha-Globin Triplication: Conversely, having extra copies of the alpha gene makes the imbalance worse [20].

Completeness Checklist for Your Lab Report

When you receive your pathology or laboratory report, check for these critical pieces of information:

  • [ ] Hemoglobin Fractions: How the lab interpreted the levels of HbE, HbF, HbA2, and HbA [21][6].
  • [ ] Platform Used: Was the test done via HPLC, Capillary Electrophoresis, or both? [9][6].
  • [ ] HBB Genotype: The specific genetic code for the mutations (e.g., HBB c.79G>A) [15][11].
  • [ ] Zygosity: Does it state “compound heterozygous” (meaning one of each different mutation)? [22].
  • [ ] Iron Status: Does the report include ferritin or transferrin saturation to rule out iron deficiency? [23][24].
  • [ ] Clinical Status: Does the report or doctor’s note specify if the patient is currently “Transfusion-Dependent” or “Non-Transfusion-Dependent”? [25].

Common questions in this guide

What is HbE/beta-thalassemia?
HbE/beta-thalassemia is an inherited blood disorder caused by an HbE variant together with a beta-thalassemia allele. These changes reduce beta-globin production, leaving excess alpha chains that damage developing and circulating red blood cells and can cause anemia and hemolysis.
What tests are used to confirm HbE/beta-thalassemia?
Doctors usually combine a blood count, hemoglobin analysis by HPLC or electrophoresis, clinical information, and molecular DNA testing. DNA testing can identify the HBB variants and clarify whether the second allele is beta-plus or beta-zero, especially when hemoglobin patterns overlap.
Can an HPLC result be mistaken for HbE trait?
Yes. Low HbF, particular beta mutations, HbE and HbA2 co-elution, iron deficiency, or related hemoglobin genotypes can make HbE/beta-thalassemia resemble HbE trait or another condition. Molecular testing may be needed when the hemoglobin pattern is not definitive.
How does a recent blood transfusion affect HbE testing?
Donor red blood cells can add different hemoglobin types to the sample and mask the patient’s own pattern. Tell the laboratory and treating clinician when the transfusion occurred so they can interpret HPLC or electrophoresis results appropriately.
What does DNA testing look for in HbE/beta-thalassemia?
Targeted PCR panels can detect common regional variants, while Sanger sequencing can find HBB changes that a limited panel misses. MLPA or Gap-PCR may be needed to identify larger deletions, so a negative limited panel does not always exclude the condition.
Can genetic modifiers change how severe HbE/beta-thalassemia is?
Yes. Variants that preserve HbF or inherited alpha-globin deletions may lessen the globin-chain imbalance, while alpha-globin triplication may worsen it. Modifier testing can provide context, but it cannot perfectly predict an individual’s course.
Which details should I check on my HbE/beta-thalassemia lab report?
Look for HbE, HbF, HbA2, and HbA fractions, the testing platform, the HBB genotype, and whether the result identifies one HbE change and one different beta-thalassemia change. Ferritin or transferrin saturation, transfusion history, and transfusion-dependent versus non-transfusion-dependent status can add important context.

Questions For You

Answer a question to get research tailored to you. Your answers are private.

Get notified when new evidence is published on Hemoglobin E-beta-thalassemia syndrome.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.What is the specific HBB mutation inherited alongside HbE, and what does this mean for my child's hemoglobin production?
  2. 2.Was my child's diagnosis confirmed with molecular DNA testing, or was it based only on HPLC/electrophoresis?
  3. 3.Were any genetic modifiers tested, such as alpha-thalassemia deletions, and how might these influence the severity of the disease?
  4. 4.If the lab report shows a low level of HbF (fetal hemoglobin), how does that change the interpretation of whether this is HbE trait or HbE/beta-thalassemia?
  5. 5.Does the lab report mention 'alpha-globin triplication,' and if so, how does that affect the risk of iron overload?

References

References (25)
  1. 1

    Engineered U7 snRNA mediates sustained splicing correction in erythroid cells from β-thalassemia/HbE patients.

    Preedagasamzin S, Nualkaew T, Pongrujikorn T, et al.

    Biochemical and biophysical research communications 2018; (499(1)):86-92 doi:10.1016/j.bbrc.2018.03.102.

    PMID: 29550480
  2. 2

    β-Thalassemia Distribution in the Old World: an Ancient Disease Seen from a Historical Standpoint.

    De Sanctis V, Kattamis C, Canatan D, et al.

    Mediterranean journal of hematology and infectious diseases 2017; (9(1)):e2017018 doi:10.4084/MJHID.2017.018.

    PMID: 28293406
  3. 3

    Oxidative instability of hemoglobin E (β26 Glu→Lys) is increased in the presence of free α subunits and reversed by α-hemoglobin stabilizing protein (AHSP): Relevance to HbE/β-thalassemia.

    Strader MB, Kassa T, Meng F, et al.

    Redox biology 2016; (8()):363-74.

    PMID: 26995402
  4. 4

    Novel players in β-thalassemia dyserythropoiesis and new therapeutic strategies.

    Arlet JB, Dussiot M, Moura IC, et al.

    Current opinion in hematology 2016; (23(3)):181-8 doi:10.1097/MOH.0000000000000231.

    PMID: 26779615
  5. 5

    Novel Therapeutic Advances in β-Thalassemia.

    Makis A, Voskaridou E, Papassotiriou I, Hatzimichael E

    Biology 2021; (10(6)) doi:10.3390/biology10060546.

    PMID: 34207028
  6. 6

    Molecular understanding of unusual HbE-β+-thalassemia with Hb phenotype similar to HbE heterozygote: simple and rapid differentiation using HbE levels.

    Jomoui W, Satthakarn S, Panyasai S

    Annals of medicine 2023; (55(2)):2267054 doi:10.1080/07853890.2023.2267054.

    PMID: 37816374
  7. 7

    Hemoglobin E Hemoglobinopathy in an Adult from Assam with Unusual Presentation: A Diagnostic Dilemma.

    Kiran SS, Aithal S, Belagavi CS

    Journal of laboratory physicians 2016; (8(2)):116-9 doi:10.4103/0974-2727.180793.

    PMID: 27365922
  8. 8

    Red blood cell indices in different hemoglobinopathies: A cross-sectional study in Eastern India.

    Nandi A, Talukdar M, Bhattacharya S, et al.

    Indian journal of pathology & microbiology 2024; (67(1)):115-120 doi:10.4103/ijpm.ijpm_1071_21.

    PMID: 38358199
  9. 9

    Molecular Characterization of Haemoglobin E.

    Ejaz S, Mustafa G, Khaliq S, Mohsin S

    JPMA. The Journal of the Pakistan Medical Association 2023; (73(12)):2357-2362 doi:10.47391/JPMA.7138.

    PMID: 38083912
  10. 10

    Hemoglobin E Associated with Hemoglobin Constant Spring: Diagnostic Challenges in Heterozygous and Homozygous States.

    Ropero P, Escribano S, Abío M, et al.

    Hemoglobin 2026; 1-7 doi:10.1080/03630269.2026.2723419.

    PMID: 42687636
  11. 11

    Evaluation of a Customized RDB-FTH Panel for β-Globin Variants in a Malaysian Tertiary Center.

    Jalil N, Azma RZ, Alaudin H, et al.

    Hemoglobin 2026; 1-9 doi:10.1080/03630269.2026.2732039.

    PMID: 42768929
  12. 12

    Prenatal Screening and Diagnosis of ß-Thalassemia in India: Is ARMS-PCR Enough?

    Ghosh S, Chakrabarti S, Bhattacharyya M

    Indian journal of hematology & blood transfusion : an official journal of Indian Society of Hematology and Blood Transfusion 2021; (37(3)):448-452 doi:10.1007/s12288-020-01370-0.

    PMID: 34267465
  13. 13

    Genotype-phenotype correlation among beta-thalassemia and beta-thalassemia/HbE disease in Thai children: predictable clinical spectrum using genotypic analysis.

    Traivaree C, Monsereenusorn C, Rujkijyanont P, et al.

    Journal of blood medicine 2018; (9()):35-41 doi:10.2147/JBM.S159295.

    PMID: 29695942
  14. 14

    Whole-exome sequencing identifies an α-globin cluster triplication resulting in increased clinical severity of β-thalassemia.

    Steinberg-Shemer O, Ulirsch JC, Noy-Lotan S, et al.

    Cold Spring Harbor molecular case studies 2017; (3(6)) doi:10.1101/mcs.a001941.

    PMID: 28667000
  15. 15

    Prenatal Diagnosis of Compound Heterozygous Beta-Thalassemia: A Report of Two Cases.

    Jha S, Jha S, Jha VC, et al.

    Cureus 2026; (18(4)):e107581 doi:10.7759/cureus.107581.

    PMID: 42181449
  16. 16

    Modifying effect of XmnI, BCL11A, and HBS1L-MYB on clinical appearances: A study on β-thalassemia and hemoglobin E/β-thalassemia patients in Indonesia.

    Rujito L, Basalamah M, Siswandari W, et al.

    Hematology/oncology and stem cell therapy 2016; (9(2)):55-63.

    PMID: 27009595
  17. 17

    Molecular Understanding of Non-Transfusion-Dependent Thalassemia Associated with Hemoglobin E-β-Thalassemia in Northeast Thailand.

    Yamsri S, Pakdee N, Fucharoen G, et al.

    Acta haematologica 2016; (136(4)):233-239 doi:10.1159/000449120.

    PMID: 27710960
  18. 18

    Essential genetic modifiers and their measurable impact in a community-recruited population analysis for non-severe hemoglobin E/β-thalassemia prenatal genetic counseling.

    Wong P, Chitsobhak T, Jittasathian S, et al.

    Blood cells, molecules & diseases 2023; (103()):102765 doi:10.1016/j.bcmd.2023.102765.

    PMID: 37353362
  19. 19

    Drug Repurposing: Hydroxyurea Therapy Improves the Transfusion-Free Interval in HbE/Beta-Thalassemia-Major Patients with the XmnI Polymorphism.

    Ghosh D, Panja A, Saha D, et al.

    Genetic testing and molecular biomarkers 2021; (25(8)):563-570 doi:10.1089/gtmb.2021.0031.

    PMID: 34406845
  20. 20

    Alpha globin gene alterations modifying the phenotype of homozygous beta thalassaemia.

    Shaw J, Patra A, Khatun A, et al.

    EJHaem 2024; (5(3)):440-446 doi:10.1002/jha2.923.

    PMID: 38895064
  21. 21

    Detection of the Hb Hoshida (HBB: C. 130 G > C) Variant in the Indian Population.

    Sen A, Dolai TK

    Hemoglobin 2026; (50(3)):264-270 doi:10.1080/03630269.2026.2671886.

    PMID: 42157746
  22. 22

    Case report: A novel 10.8-kb deletion identified in the β-globin gene through the long-read sequencing technology in a Chinese family with abnormal hemoglobin testing results.

    Shao M, Wan Y, Cao W, et al.

    Frontiers in medicine 2023; (10()):1192279 doi:10.3389/fmed.2023.1192279.

    PMID: 37521358
  23. 23

    Laboratory diagnosis of thalassemia.

    Brancaleoni V, Di Pierro E, Motta I, Cappellini MD

    International journal of laboratory hematology 2016; (38 Suppl 1()):32-40 doi:10.1111/ijlh.12527.

    PMID: 27183541
  24. 24

    Reduced hepcidin expression enhances iron overload in patients with HbE/β-thalassemia: Α comparative cross-sectional study.

    Saad HKM, Taib WRW, Ismail I, et al.

    Experimental and therapeutic medicine 2021; (22(6)):1402 doi:10.3892/etm.2021.10838.

    PMID: 34675995
  25. 25

    Challenges in chronic transfusion for patients with thalassemia.

    Lal A

    Hematology. American Society of Hematology. Education Program 2020; (2020(1)):160-166 doi:10.1182/hematology.2020000102.

    PMID: 33275743

This page explains HbE/beta-thalassemia biology and diagnostic testing for educational purposes only; it does not replace medical advice. Ask a hematologist or genetics professional to interpret your or your child’s laboratory results.